VYGR Earnings & Financial Statements
Voyager Therapeutics, Inc.
$2.10
+$0.09(+4.23%)
45
Overall
60
Value
36
Tech
39
Quality
Market Cap
$123.85M
Volume
196.78K
52W Range
$2.33 - $5.55
Target Price
$15.38
VYGR earnings and financial statements: Voyager Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VYGR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $40.37M | $80.00M | $250.01M | $40.91M | $37.41M |
| Operating income | -$131.84M | -$83.29M | $122.01M | -$50.84M | -$73.62M |
| EBITDA | -$121.22M | -$73.37M | $126.42M | -$41.98M | -$68.45M |
| Net income | -$119.72M | -$65.00M | $132.33M | -$46.41M | -$71.20M |
| EPS (diluted) | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $252.28M | $393.05M | $351.28M | $159.36M | $193.85M |
| Total liabilities | $56.20M | $93.29M | $114.96M | $100.34M | $98.80M |
| Shareholders’ equity | $196.08M | $299.76M | $236.32M | $59.02M | $95.06M |
| Cash and equivalents | $65.30M | $71.37M | $68.80M | $98.96M | $117.43M |
| Long-term debt | $28.66M | $36.50M | $17.09M | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$132.47M | -$15.31M | $77.92M | -$12.51M | -$53.52M |
| Capital expenditure | -$2.60M | -$3.52M | -$3.26M | -$2.49M | -$1.61M |
| Free cash flow | -$135.06M | -$18.83M | $74.66M | -$15.00M | -$55.13M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VYGR | $2.10 | +4.2% | 196.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Voyager Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW